Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Moodys
Merck
Colorcon
Medtronic

Last Updated: October 1, 2022

VOGELXO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Vogelxo patents expire, and when can generic versions of Vogelxo launch?

Vogelxo is a drug marketed by Upsher Smith Labs and is included in one NDA. There are three patents protecting this drug.

This drug has eight patent family members in eight countries.

The generic ingredient in VOGELXO is testosterone. There are sixty-nine drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vogelxo

A generic version of VOGELXO was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.

  Try it Free

Summary for VOGELXO
Drug patent expirations by year for VOGELXO
Drug Prices for VOGELXO

See drug prices for VOGELXO

Recent Clinical Trials for VOGELXO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Upsher-Smith LaboratoriesPhase 4

See all VOGELXO clinical trials

Pharmacology for VOGELXO
Drug Class Androgen
Mechanism of ActionAndrogen Receptor Agonists

US Patents and Regulatory Information for VOGELXO

VOGELXO is protected by three US patents.

Patents protecting VOGELXO

Testosterone gel compositions and related methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE

Testosterone gel compositions and related methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE

Testosterone gel compositions and related methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher Smith Labs VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399-003 Jun 4, 2014 BX RX No No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upsher Smith Labs VOGELXO testosterone GEL;TRANSDERMAL 204399-002 Jun 4, 2014 AB2 RX No No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upsher Smith Labs VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399-003 Jun 4, 2014 BX RX No No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for VOGELXO

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Warner Chilcott UK Ltd. Intrinsa testosterone EMEA/H/C/000634
Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
Warner Chilcott  Deutschland GmbH Livensa testosterone EMEA/H/C/000630
Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for VOGELXO

See the table below for patents covering VOGELXO around the world.

Country Patent Number Title Estimated Expiration
Canada 2857286 COMPOSITIONS DE GEL DE TESTOSTERONE ET PROCEDES CONNEXES (TESTOSTERONE GEL COMPOSITIONS AND RELATED METHODS) See Plans and Pricing
Israel 246134 See Plans and Pricing
Hong Kong 1223852 睪丸酮凝膠組合物及相關方法 (TESTOSTERONE GEL COMPOSITIONS AND RELATED METHODS) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKinsey
Merck
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.